Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: MarketLine (a Datamonitor Company)
$175.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Astellas Pharma Inc receives approval for additional indication for Hypnosedative, Dormicum in Japan


Friday, 20 Dec 2013 01:00am EST 

Astellas Pharma Inc:Says it received the approval of an additional indication for hypnosedative, Dormicum Injection 10 mg (generic name: midazolam) from the Ministry of Health, Labour and Welfare in Japan.Says the new indication is for use in sedation during surgery and procedures for dental, oral and maxillofacial care. 

Company Quote

1409.0
-2.5 -0.18%
10:22pm EDT